Leveraging Bioorthogonal Click Chemistry to Improve 225Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma.
Sophie PotyLukas Michael CarterKomal MandleywalaRosemery MembrenoDalya Abdel-AttiAshwin RagupathiWolfgang W ScholzBrian M ZeglisJason S LewisPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
The ability of 225Ac-PRIT to deliver a radiotherapeutic payload while simultaneously reducing the off-target toxicity normally associated with RIT suggests that the clinical translation of this approach will have a profound impact on PDAC therapy.